HBM HEALTHCARE INVESTMENTS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 188 CHF | 0.00% |
|
0.00% | +2.96% |
| 04-03 | HBM Healthcare Investments Warns of CHF1 Million Loss for FY24 | MT |
| 01-22 | HBM Healthcare Investments AG Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Investment Management & Fund Operators
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.96% | 1.42B | D+ | ||
| +31.41% | 12.02B | - | - | |
| +14.40% | 3.06B | B- | ||
| -8.46% | 1.22B | - | - | |
| +1.15% | 616M | - | ||
| -10.84% | 579M | - | B+ | |
| +35.79% | 577M | - | D+ | |
| -4.17% | 492M | - | - | |
| +33.85% | 488M | - | - | |
| +3.90% | 304M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HBMN Stock
- Ratings HBM Healthcare Investments AG
